Literature DB >> 19029996

Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.

Daniel Benten1, Katharina Staufer, Martina Sterneck.   

Abstract

Improvements in surgical technique and the introduction of several new immunosuppressive medications mean that outcome after orthotopic liver transplantation (OLT) has improved continuously over the past 15 years. Given the increasing longevity of patients after OLT, the recognition and prevention of long-term complications after transplantation have become ever more important. With respect to graft function, physicians responsible for the everyday care of patients following transplantation should be particularly aware of the risk of late and chronic rejection episodes and of recurrence of the underlying liver disease. The major challenge of post-transplant care is, however, how best to prevent and manage the long-term adverse effects caused by the immunosuppressive medications prescribed. Screening investigations for early diagnosis of malignancy, strict control of cardiovascular risk factors, preservation of renal function, and prevention of infections are, therefore, fundamental. This Review suggests guidelines for the management of OLT recipients to improve long-term survival, overall outcome and health-related quality of life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029996     DOI: 10.1038/ncpgasthep1312

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  103 in total

1.  Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2 to 19 years follow-up.

Authors:  R Kashyap; A Jain; J Reyes; A J Demetris; K A Elmagd; S F Dodson; W Marsh; V Madariaga; G Mazariegos; D Geller; C A Bonham; T Cacciarelli; P Fontes; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

Review 2.  Cardiovascular risk factors after liver transplantation.

Authors:  Santiago J Muñoz; Hisham Elgenaidi
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

3.  Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation.

Authors:  Giuseppe Fusai; Parveen Dhaliwal; Nancy Rolando; Caroline Anne Sabin; David Patch; Brian Ritchie Davidson; Andrew Kenneth Burroughs; Keith Rolles
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

4.  Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.

Authors:  D K Imagawa; S Dawson; C D Holt; P S Kirk; F M Kaldas; C R Shackleton; P Seu; S M Rudich; M M Kinkhabwala; P Martin; L I Goldstein; N G Murray; P I Terasaki; R W Busuttil
Journal:  Transplantation       Date:  1996-10-15       Impact factor: 4.939

5.  Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up.

Authors:  Jang I Moon; Ralph Barbeito; Raquel N Faradji; Jeffrey J Gaynor; Andreas G Tzakis
Journal:  Transplantation       Date:  2006-12-27       Impact factor: 4.939

Review 6.  Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management.

Authors:  Ian Schreibman; Arie Regev
Journal:  MedGenMed       Date:  2006-05-03

7.  Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss.

Authors:  M D Stegall; G T Everson; G Schroter; F Karrer; B Bilir; T Sternberg; R Shrestha; M Wachs; I Kam
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

8.  Employment after liver transplantation.

Authors:  P C Adams; C N Ghent; D R Grant; W J Wall
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

9.  Psychiatric and psychosocial outcome of orthotopic liver transplantation.

Authors:  Hans-Bernd Rothenhäusler; Sigrid Ehrentraut; Hans-Peter Kapfhammer; Christina Lang; Reinhart Zachoval; Manfred Bilzer; Gustav Schelling; Alexander L Gerbes
Journal:  Psychother Psychosom       Date:  2002 Sep-Oct       Impact factor: 17.659

10.  Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.

Authors:  Paul J Taylor; Paul A Kubler; Stephen V Lynch; Joan Allen; Maree Butler; Peter I Pillans
Journal:  Ann Pharmacother       Date:  2003-12-19       Impact factor: 3.154

View more
  8 in total

1.  Evolution and trends in reconstructive facial surgery: an update.

Authors:  Oladimeji A Akadiri
Journal:  J Maxillofac Oral Surg       Date:  2012-05-13

Review 2.  Long-term medical management of the liver transplant recipient: what the primary care physician needs to know.

Authors:  Siddharth Singh; Kymberly D Watt
Journal:  Mayo Clin Proc       Date:  2012-07-03       Impact factor: 7.616

3.  Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.

Authors:  Alessia De Caneva; Fabiola Porro; Giulia Bortolussi; Riccardo Sola; Michela Lisjak; Adi Barzel; Mauro Giacca; Mark A Kay; Kristian Vlahoviček; Lorena Zentilin; Andrés F Muro
Journal:  JCI Insight       Date:  2019-06-18

4.  Medical Management of Metabolic Complications of Liver Transplant Recipients.

Authors:  Abbey Barnard; Peter Konyn; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

Review 5.  Care of the liver transplant patient.

Authors:  Mamatha Bhat; Said Al-Busafi; Marc Deschênes; Peter Ghali
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04

Review 6.  Recent advances in understanding and managing liver transplantation.

Authors:  Francesco Paolo Russo; Alberto Ferrarese; Alberto Zanetto
Journal:  F1000Res       Date:  2016-12-21

7.  Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany.

Authors:  Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

Review 8.  Cystic fibrosis related liver disease--another black box in hepatology.

Authors:  Katharina Staufer; Emina Halilbasic; Michael Trauner; Lili Kazemi-Shirazi
Journal:  Int J Mol Sci       Date:  2014-08-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.